HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Cellyan Biotechnology Co., Ltd
Financials through fiscal 2025, year ended Mar 31, 2025Last filing: 20-F on Aug 7, 2026
$0.11+0.00 (+1.81%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.0678 (−90.49%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Cellyan Biotechnology Co., Ltd grew revenue 21.7% to $20.31M over fiscal 2025. Free cash flow was $499.30K.
Revenue
$20.31M
+21.7% vs. a year earlier
Operating income
-$2.28M
FY2025
Free cash flow
$499.30K
FY2025
EPS, diluted
-$0.00
-101.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $20.31M
- Net income
- -$27.06K
- EPS, diluted
- -$0.00
- Free cash flow
- $499.30K
Three years at a glance
Fiscal years 2023 to 2025, USD
Revenue
$20.31M+21.7% YoY
Gross profit
$2.42M-32.1% YoY
Operating income
-$2.28M
Net income
-$27.06K-102.0% YoY
EPS, diluted
-$0.00-101.7% YoY
Free cash flow
$499.30K
Reported period